47 results about "Tranilast" patented technology

Combination therapy is disclosed herein for the treatment an arthritic condition (e.g. rheumatoid arthritis, osteoarthritis or psoriatic arthritis). The therapies disclosed herein comprise administering tranilast or an analogous compound in combination with a pharmaceutical agent, such as a non-steroidal anti-inflammatory drug, a disease-modifying drug, a COX-2 inhibitor, an antibiotic, an analgesic or combination thereof.

Disclosed is a pharmaceutical composition comprising tranilast or a pharmaceutically acceptable salt thereof and allopurinol or a pharmaceutically acceptable salt thereof, wherein the amount by weight of said allopurinol or pharmaceutically acceptable salt thereof in said composition is greater than the amount by weight of said tranilast or pharmaceutically acceptable salt thereof in said composition.

A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain.

The invention relates to a tranilast medicine coat controlled release eluting bracket, pertaining to the field of medicine and medical appliance. The invention takes tranilast as the active component;three layers of a medicine loading layer, a controlled release layer and a protecting film layer are at the surface of the bracket. The bracket coat is evenly distributed on the surface of the bracket without crack and exfoliating phenomena; the original morphological structure can be kept after expanding. Proved by animal experiment result, the invention can effectively restrain the coronary hyperplasia and restenosis and markedly reduce the function of restraining the blood vessel endothelial cell at the same time; compared with the single coat or double coat structure of the existing drug-eluting bracket, the bracket of the invention can prevent the restenosis of the bracket, and has the functions of prventing bracket thrombus from being formed and promoting the early reparation of thebracket endothelium.

Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.

Methods for treating eye diseases associated with inflammation and / or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

The present invention provides an oral pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease. That is, the present invention relates to a pharmaceutical composition for inhibiting the progression of intestinal stricture associated with Crohn's disease which comprises as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid (generic name: tranilast) or a pharmaceutically acceptable salt thereof. The present invention can provide a pharmaceutical composition useful as an agent for inhibiting the progression of intestinal stricture associated with Crohn's disease for medical therapy.

The present invention relates, in general, to fibroproliferative disorders, and, in particular, to a method of treating, preventing or reducing fibroproliferative disorders by administering to a mammal in need a composition comprising pharmacologically effective doses of a cytokine modifier, such as tranilast or pirfenidone, and an anti-oxidant which is a precursor of glutathione, such as N-acetyl-cysteine, or their pharmaceutically acceptable derivatives, salts, metabolites, or structural or functional analogues thereof.

The invention provides a method for preparing tranilast. The method is that 3, 4-dimethyl benzaldehyde is used as a starting material subjected to condensation reaction with malonic acid by pyridine catalyzing to synthesize 3, 4-dimethoxycinnamic acid; the 3, 4-dimethoxycinnamic acid is condensed with methyl anthranilate to generate tranilast methyl ester; the tranilast methyl ester is hydrolyzed through sodium hydroxide to obtain tranilast. The total yield of tranilast is up to 67%. The method is short in process line, simple to operate, high in yield, low in production cost, stable, reliable, and simple to operate; the high-purity tranilast raw medicine can be obtained with high yield; the production cost can be completely reduced; the emission of pollutants can be decreased.

A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain.

The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering Tranilast, or an analog thereof, directly to tissue surfaces in the body cavity in amounts and under conditions effective to inhibit formation of adhesions, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure.

The present invention provides a composition for the inhibition of and promotion of recovery from muscular fatigue or muscular damage and diseases associated therewith, in particular, muscular fatigue or muscular damage caused by exercise stress and diseases associated therewith, and a composition for the prevention or treatment of myofibrosis during the restoration at the damaged part associated with or incidental to surgical injury or surgical procedure, which are characterized by comprising as an active ingredient N-(3,4-dimethoxy-cinnnamoyl)anthranilic acid (generic name: tranilast) or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, and a method for use thereof.

Belonging to the field of medical technologies, the invention relates to a prescription and preparation method for topical gel and ointment dosage forms containing tranilast component, and therapeutic effects of the dosage forms in keloid and hypertrophic scar fields. The topical gel and ointment contain tranilast, a cosolvent, a substrate, a humectant, a penetration enhancer, a preservative, a pH regulator, purified water and other ingredients. The preparation method includes the steps of: 1. taking a prescribed amount of the substrate, adding a proper amount of purified water, performing full swelling at 20-80DEG C, adjusting the pH to less than 5, adding a prescribed amount of humectant, and conducting heat preservation to obtain A; 2. taking a prescribed amount of tranilast, the cosolvent, the preservative, and a proper amount of purified water, carrying out heating dissolving at 20-80DEG C, and performing heat preservation to obtain B; and 3. Pouring B into A, conducting heat preservation and swelling, and stirring the mixture evenly, thus obtaining the products. The tranilast gel and ointment provided by the invention have the pharmacological activity of treating hypertrophic scars and keloids.

The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering Tranilast, or an analog thereof, directly to tissue surfaces in the body cavity in amounts and under conditions effective to inhibit formation of adhesions, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure.

The invention relates to an oral compound pharmaceutic preparation for treating asthma, which contains tranilast shown as the formula (I) and salbutamol sulfate shown as the formula (II) or other pharmaceutically allowed active ingredients. The invention also relates to the application of compounds shown as formulas (I) and (II) or pharmaceutically allowed salts thereof in the preparation of an oral therapeutical agent for treating asthma.

The invention relates to a composite gel containing a traditional Chinese medicine composition and calcium ion and a preparation method thereof. The composite gel containing the traditional Chinese medicine composition and calcium ion is composed of the following substances in percent by weight: 10-18% of the traditional Chinese medicine composition, 30-50% of hyaluronic acid or chitosan, 1.2-10.5% of a salt-resistant medicine, 0.03-0.5% of a hormone medicine, 0.15-0.25% of CaCl2, 5.0-15.0% of tranilast and the balance deionized water. The traditional Chinese medicine composition is obtained though clathration of ligusticum wallichii, radix salviae miltiorrhizae and sanguis draxonis by cyclodextrin. The composite gel containing the traditional Chinese medicine composition and calcium ion has relatively good postoperative antistick effect.

Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.

The present invention discloses the recipe and preparation process of eye drop containing tranilast for treating allergic conjunctivitis. The recipe contains also supplementary material, including meglumine, citric acid, PVP-K30 and nipalgin. The medicine of the present invention has high stability and no thrill on eyes.

Methods for treating eye diseases associated with inflammation and / or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

The present invention relates generally to a method of modulating cellular functioning. More particularly, the present invention relates to a method of modulating B cell functioning, for example B cell proliferation, utilising an IDO-mediated tryptophan metabolite as herein defined (particular examples of such IDO-mediated tryptophan metabolites include 3-hydroxykynurenic acid, 3-hydroxyanthranilic acid, picolinic acid, quinolinic acid and tranilast). The method of the present invention is useful, inter alia, in the treatment and / or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate B cell functioning such as antibody production, autoimmune conditions and B cell proliferation and neoplasias. In a related aspect, the present invention is directed to a method of therapeutically and / or prophylactically treating rheumatoid arthritis via the administration of the above-mentioned compounds.

The invention discloses application of tranilast-combined anti-tuberculosis medicaments in preparation of a medicament for treating tuberculosis, and at least two of the tranilast-combined anti-tuberculosis medicaments (isonicotinyl hydrazine, rifampicin, pyrazinoic acid amide and ethambutol) are adopted. After the medicament combination is applied for 50 days, a patient can feel that skin damage is obviously alleviated; after the medicament combination is applied for 3 to 4 months, skin damage of the patient almost completely disappears with a speed obviously greater than that of a control group of pure anti-tuberculosis treatment, so that the anti-tuberculosis treatment course is greatly shortened, tissue damage such as atrophic scar formation and pigmentation can be reduced, and no obvious adverse reaction exists, which indicates that the tranilast-combined classical anti-tuberculosis medicaments have a synergistic anti-tuberculosis effect, are capable of obviously shortening the anti-tuberculosis treatment course and enhancing the anti-tuberculosis curative effect when used for resisting the tuberculosis, are good in toleration and relatively high in compliance of patients, free from obvious adverse reaction, and relatively good in clinical curative effect and security, and are expected to become necessary medicaments for combined treatment of the tuberculosis.

The present disclosure relates to a synergistic mixture of betamethasone valerate and tranilast combined with a transdermal gel using skin permeation enhancement for application in scars for reducing or preventing the abnormal scar formation, specially keloids and hypertrophic scars. The disclosed synergistic mixture may exhibit permeation enhancing properties. The transdermal gel may include a mixture of silicone, phosphatidylcholine, pracaxi oil, and seje oil; one or more oils having essential fatty acids, behenic acid, oleic acid; one or more skin lipids; a butter having linoleic acid and linolenic acid; and solvents as transdermal penetration enhancers.

The invention belongs to the field of pharmaceutical chemistry, and provides novel applications of tranilast, and especially applications of tranilast in preparation of medicines used for treating NLRP3 inflammasome related diseases. It is shown by experiments that tranilast is capable of reducing IL-1beta and IL-18 maturation secretion, blocking obesity development, and preventing type II diabetes through specific inhibition on NLRP3 inflammasome activation, and treating peritonitis and gout caused by NLRP3 inflammasome stimulant urate crystal (MSU) accumulation, and Muckle Wells syndromes caused by NLRP3 mutation preferably at the same time.

The invention aims to provide a compound oral disintegrating tablet preparation which is composed of tranilast and salbutamol sulfate, and a preparation method thereof. The adopted specific technical proposal for achieving the purpose of the invention is as follows: the compound tranilast oral disintegrating tablet preparation is characterized in that the formula of the preparation is composed of the following components by parts by weight (by 1000 tablets): 80.0g of tranilast, 2.4g of salbutamol sulfate, 5-30g of disintegrant, 10-80g of filling agent, 5-25g of effervescing agent, 0.5-20g of flavoring agent and 0.3-3g of lubricant. The compound oral disintegrating tablet preparation which is prepared by the method can solve the shortcomings of the two drugs on the pharmacological effects during the treatment process of bronchial asthma and allow the compound oral disintegrating tablet preparation to relieve the asthma instantly and maintain and consolidate the effect; furthermore, the compound oral disintegrating tablet preparation has convenient administration, rapid onset of action, high bioavailability and good taste. The preparation method of the preparation has simple steps and low cost.

The invention discloses the application of an inhibitor of NLRP3 inflammasome in the preparation of medicine for treating pituitary adenoma and the medicine for treating pituitary adenoma. NLRP3 inflammasome inhibitors are MCC950 or tranilast. Drugs containing NLRP3 inflammasome inhibitors may enable the treatment of pituitary adenomas. NLRP3 inflammasome inhibitors bring good news to patients with pituitary adenomas.

The object of the present invention is to provide a formulation with the effect of effectively suppressing or inhibiting amyloid fibril formation by the dissolution, elimination (discharge), etc. of amyloid fibril formation in vivo.If an agent for suppressing or inhibiting an amyloid fibril formation comprising tranilast or a pharmacologically acceptable salt thereof as an active ingredient is administered by a method such as oral administration, amyloid fibril formation can be effectively suppressed or inhibited in vivo as a result of effects such as amyloid fibril dissolution or elimination (discharge). Therefore, it is possible to prevent or treat amyloid plaques, in which amyloid fibrils formed by the aggregation of amyloid protein have been deposited, and to prevent or treat diseases arising from amyloid fibril deposition, that is, diseases arising from the deposited amyloid fibrils themselves and diseases that cause dysfunction of organs or tissues as a result of amyloid fibril deposition.